[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:pancreatic-carcinoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":315,"states":387},"Pancreatic Carcinoma",265,225,[8,16,23,30,36,43,49,55,61,67,73,79,85,91,97,103,109,115,121,128,134,140,146,152,158,164,170,176,182,188,194,200,206,212,218,225,231,237,243,249,255,261,267,273,279,285,291,297,303,309],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06479239","Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:15:57.572488Z","2026-07-05T05:32:16.755246Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06141031","Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma",[20],"Phase 1","2026-08-26T02:15:51.395565Z","2026-05-29T15:36:40.167823Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT04683315","PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples",[27],"Phase 2","2026-08-26T02:18:38.865010Z","2026-05-05T02:43:29.732070Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT06850623","Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer",[27],"2026-08-26T02:17:50.500039Z","2026-05-05T02:43:29.382081Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":41,"content_modified":42},"NCT04048278","Lidocaine Infusion in Pancreatic Cancer",[40],"Early Phase 1","2026-08-26T02:19:05.360997Z","2026-05-05T02:43:29.334628Z",{"nct_id":44,"title":45,"phases":46,"status":13,"updated_at":47,"content_modified":48},"NCT04150042","SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells",[20],"2026-08-26T02:18:58.141497Z","2026-05-05T02:43:29.297862Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":53,"content_modified":54},"NCT05679674","Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer",[],"2026-08-26T02:18:09.641312Z","2026-05-05T02:43:29.193858Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT06906562","A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations",[27],"2026-08-26T02:16:15.345907Z","2026-05-05T02:43:29.157055Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT04858334","APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation",[27],"2026-08-26T02:15:52.238965Z","2026-05-05T02:43:29.056915Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT02598349","Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas",[27],"2026-08-26T02:16:47.762107Z","2026-05-05T02:43:28.987885Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT05391126","GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care",[],"2026-08-26T02:19:20.945539Z","2026-05-05T02:43:28.986728Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT06782932","Comparing Neoadjuvant\u002FAdjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer",[12],"2026-08-26T02:15:11.740957Z","2026-05-05T02:43:28.865630Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT04858009","Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis",[27],"2026-08-26T02:18:00.873391Z","2026-05-05T02:43:28.851444Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT06228599","Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence",[],"2026-08-26T02:15:10.362237Z","2026-05-05T02:43:28.847431Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT05764720","Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach",[],"2026-08-26T02:15:02.712396Z","2026-05-05T02:43:28.843044Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT04789486","Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer",[12],"2026-08-26T02:17:56.243868Z","2026-05-05T02:43:28.826745Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT04543071","Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma",[27],"2026-08-26T02:17:23.750999Z","2026-05-05T02:43:28.733022Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT06736717","Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer",[12],"2026-08-26T02:16:59.895916Z","2026-05-05T02:43:28.539985Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":126,"content_modified":127},"NCT03257033","Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC",[125],"Phase 3","2026-08-26T02:17:07.954622Z","2026-05-05T02:43:28.314963Z",{"nct_id":129,"title":130,"phases":131,"status":13,"updated_at":132,"content_modified":133},"NCT04911816","Neoadjuvant mFOLFIRINOX With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adenocarcinoma",[12],"2026-08-26T02:16:52.995882Z","2026-05-05T02:43:28.312997Z",{"nct_id":135,"title":136,"phases":137,"status":13,"updated_at":138,"content_modified":139},"NCT03652428","Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)",[12],"2026-08-26T02:18:17.007929Z","2026-05-05T02:43:28.281398Z",{"nct_id":141,"title":142,"phases":143,"status":13,"updated_at":144,"content_modified":145},"NCT07043270","24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC",[27],"2026-08-26T02:15:04.877798Z","2026-05-05T02:43:28.221053Z",{"nct_id":147,"title":148,"phases":149,"status":13,"updated_at":150,"content_modified":151},"NCT02843945","Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source",[12],"2026-08-26T02:15:09.079045Z","2026-05-05T02:43:28.010282Z",{"nct_id":153,"title":154,"phases":155,"status":13,"updated_at":156,"content_modified":157},"NCT07549958","PhIbRandomGemcitabine(G)w\u002For w\u002FOut Pitavastatin(P)MainTx UnresecPancreaticAdenocarcinoma(uPDAC)",[20],"2026-08-26T02:16:34.792807Z","2026-05-05T02:43:27.916542Z",{"nct_id":159,"title":160,"phases":161,"status":13,"updated_at":162,"content_modified":163},"NCT05141513","Intraoperative Radiation Therapy After Stereotactic Body Radiation Therapy and Chemotherapy in Treatment of Pancreatic Adenocarcinoma",[20],"2026-08-03T02:10:37.231905Z","2026-05-05T02:43:27.839067Z",{"nct_id":165,"title":166,"phases":167,"status":13,"updated_at":168,"content_modified":169},"NCT05919238","Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocarcinoma",[20],"2026-08-26T02:18:30.351130Z","2026-05-05T02:43:27.754297Z",{"nct_id":171,"title":172,"phases":173,"status":13,"updated_at":174,"content_modified":175},"NCT03492671","Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer",[27],"2026-08-26T02:19:13.549512Z","2026-05-05T02:43:27.590374Z",{"nct_id":177,"title":178,"phases":179,"status":13,"updated_at":180,"content_modified":181},"NCT05825066","Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma",[27],"2026-08-26T02:19:09.651016Z","2026-05-05T02:43:27.278151Z",{"nct_id":183,"title":184,"phases":185,"status":13,"updated_at":186,"content_modified":187},"NCT06205849","Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer",[20],"2026-08-26T02:19:14.560989Z","2026-05-05T02:43:27.056315Z",{"nct_id":189,"title":190,"phases":191,"status":13,"updated_at":192,"content_modified":193},"NCT06411691","KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer",[20],"2026-08-26T02:18:13.438956Z","2026-05-05T02:43:26.921409Z",{"nct_id":195,"title":196,"phases":197,"status":13,"updated_at":198,"content_modified":199},"NCT05053971","Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors",[12],"2026-08-26T02:17:43.321968Z","2026-05-05T02:43:26.770363Z",{"nct_id":201,"title":202,"phases":203,"status":13,"updated_at":204,"content_modified":205},"NCT04115163","Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer",[27],"2026-08-03T02:56:25.717758Z","2026-05-05T02:43:26.769646Z",{"nct_id":207,"title":208,"phases":209,"status":13,"updated_at":210,"content_modified":211},"NCT07254091","Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Pancreatic Cancer",[40],"2026-08-26T02:18:36.226508Z","2026-05-05T02:35:31.867832Z",{"nct_id":213,"title":214,"phases":215,"status":13,"updated_at":216,"content_modified":217},"NCT06693986","Adenovirus (RGDCRAdCOX2F)",[20],"2026-08-26T02:18:54.586325Z","2026-05-05T02:35:31.766915Z",{"nct_id":219,"title":220,"phases":221,"status":13,"updated_at":223,"content_modified":224},"NCT06989437","A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue",[222],"Phase 2\u002FPhase 3","2026-08-26T02:16:41.943926Z","2026-05-05T02:35:31.762099Z",{"nct_id":226,"title":227,"phases":228,"status":13,"updated_at":229,"content_modified":230},"NCT03484299","Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma",[20],"2026-08-26T02:15:50.539717Z","2026-04-29T02:57:57.107431Z",{"nct_id":232,"title":233,"phases":234,"status":13,"updated_at":235,"content_modified":236},"NCT04665947","First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer",[40],"2026-08-26T02:15:56.561131Z","2026-04-29T02:57:57.105988Z",{"nct_id":238,"title":239,"phases":240,"status":13,"updated_at":241,"content_modified":242},"NCT07157033","A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.",[12],"2026-08-26T02:18:18.766496Z","2026-04-29T02:57:57.104173Z",{"nct_id":244,"title":245,"phases":246,"status":13,"updated_at":247,"content_modified":248},"NCT03322995","Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial",[27],"2026-08-26T02:17:09.131534Z","2026-04-29T02:57:57.070766Z",{"nct_id":250,"title":251,"phases":252,"status":13,"updated_at":253,"content_modified":254},"NCT07066657","A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors",[20],"2026-08-26T02:17:45.190188Z","2026-07-30T01:46:14.415478Z",{"nct_id":256,"title":257,"phases":258,"status":13,"updated_at":259,"content_modified":260},"NCT07300150","A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors",[20],"2026-08-26T02:17:40.683658Z","2026-07-19T19:36:05.071253Z",{"nct_id":262,"title":263,"phases":264,"status":13,"updated_at":265,"content_modified":266},"NCT05277168","A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS",[12],"2026-08-26T02:17:55.355429Z","2026-07-05T05:32:16.798807Z",{"nct_id":268,"title":269,"phases":270,"status":13,"updated_at":271,"content_modified":272},"NCT07563738","A 2-part Phase 1\u002F2 Open-label Trial on ODM-212",[12],"2026-08-26T02:15:26.669629Z","2026-05-13T02:55:06.727821Z",{"nct_id":274,"title":275,"phases":276,"status":13,"updated_at":277,"content_modified":278},"NCT03943004","Trial of DFP-14927 in Advanced Solid Tumors",[20],"2026-08-26T02:16:44.178623Z","2026-05-05T02:43:29.398880Z",{"nct_id":280,"title":281,"phases":282,"status":13,"updated_at":283,"content_modified":284},"NCT05458219","A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors",[20],"2026-08-26T02:17:42.501124Z","2026-05-05T02:43:29.294686Z",{"nct_id":286,"title":287,"phases":288,"status":13,"updated_at":289,"content_modified":290},"NCT06885034","A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed",[12],"2026-08-26T02:17:54.420226Z","2026-05-05T02:43:29.137396Z",{"nct_id":292,"title":293,"phases":294,"status":13,"updated_at":295,"content_modified":296},"NCT06782555","A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab",[12],"2026-08-26T02:15:27.567165Z","2026-05-05T02:43:28.960593Z",{"nct_id":298,"title":299,"phases":300,"status":13,"updated_at":301,"content_modified":302},"NCT04939610","A Study of 177Lu-FAP-2286 in Advanced Solid Tumors",[12],"2026-08-26T02:17:29.353236Z","2026-05-05T02:43:28.824951Z",{"nct_id":304,"title":305,"phases":306,"status":13,"updated_at":307,"content_modified":308},"NCT06244771","A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors",[12],"2026-08-26T02:19:12.219640Z","2026-05-05T02:43:28.733888Z",{"nct_id":310,"title":311,"phases":312,"status":13,"updated_at":313,"content_modified":314},"NCT06576037","Phase Ib Study of CBP-1019 in Combination With FOLFOX +\u002F- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin",[20],"2026-08-26T02:17:33.002248Z","2026-05-05T02:43:27.946272Z",[316,320,323,327,331,335,339,342,346,349,352,355,359,362,365,368,372,375,378,381,384],{"biomarker":317,"count":318,"slug":319},"BRCA1 Gene",15,"brca1-gene",{"biomarker":321,"count":318,"slug":322},"BRCA2 Gene","brca2-gene",{"biomarker":324,"count":325,"slug":326},"Partner and Localizer of BRCA2",14,"partner-and-localizer-of-brca2",{"biomarker":328,"count":329,"slug":330},"GTPase KRas",10,"gtpase-kras",{"biomarker":332,"count":333,"slug":334},"ATM Gene",9,"atm-gene",{"biomarker":336,"count":337,"slug":338},"CDKN2A Gene",6,"cdkn2a-gene",{"biomarker":340,"count":337,"slug":341},"DNA Mismatch Repair Protein Mlh1","dna-mismatch-repair-protein-mlh1",{"biomarker":343,"count":344,"slug":345},"MRC1 wt Allele",5,"mrc1-wt-allele",{"biomarker":347,"count":344,"slug":348},"MSH2 Gene","msh2-gene",{"biomarker":350,"count":344,"slug":351},"MSH6 Gene","msh6-gene",{"biomarker":353,"count":344,"slug":354},"PMS2 Gene","pms2-gene",{"biomarker":356,"count":357,"slug":358},"EPCAM Gene",4,"epcam-gene",{"biomarker":360,"count":357,"slug":361},"MTAP Gene","mtap-gene",{"biomarker":363,"count":357,"slug":364},"STK11 Gene","stk11-gene",{"biomarker":366,"count":357,"slug":367},"Trypsin-1","trypsin-1",{"biomarker":369,"count":370,"slug":371},"ERBB2 Gene",3,"erbb2-gene",{"biomarker":373,"count":370,"slug":374},"HLA-A Gene","hla-a-gene",{"biomarker":376,"count":370,"slug":377},"MSI1 Gene","msi1-gene",{"biomarker":379,"count":370,"slug":380},"Prolyl Endopeptidase FAP","prolyl-endopeptidase-fap",{"biomarker":382,"count":370,"slug":383},"Soluble Epidermal Growth Factor Receptor","soluble-epidermal-growth-factor-receptor",{"biomarker":385,"count":370,"slug":386},"TP53 Gene","tp53-gene",[388,392,395,399,403,407,411,415,419,423,427,431,434,438,442,445,448,452,456,460,464,468,472,475],{"state":389,"count":390,"slug":391},"California",85,"california",{"state":393,"count":390,"slug":394},"Texas","texas",{"state":396,"count":397,"slug":398},"New York",66,"new-york",{"state":400,"count":401,"slug":402},"Florida",65,"florida",{"state":404,"count":405,"slug":406},"Ohio",44,"ohio",{"state":408,"count":409,"slug":410},"Massachusetts",40,"massachusetts",{"state":412,"count":413,"slug":414},"Michigan",39,"michigan",{"state":416,"count":417,"slug":418},"Pennsylvania",38,"pennsylvania",{"state":420,"count":421,"slug":422},"Tennessee",36,"tennessee",{"state":424,"count":425,"slug":426},"North Carolina",33,"north-carolina",{"state":428,"count":429,"slug":430},"Maryland",31,"maryland",{"state":432,"count":429,"slug":433},"Virginia","virginia",{"state":435,"count":436,"slug":437},"Colorado",29,"colorado",{"state":439,"count":440,"slug":441},"Minnesota",27,"minnesota",{"state":443,"count":440,"slug":444},"Missouri","missouri",{"state":446,"count":440,"slug":447},"New Jersey","new-jersey",{"state":449,"count":450,"slug":451},"Illinois",26,"illinois",{"state":453,"count":454,"slug":455},"Arizona",24,"arizona",{"state":457,"count":458,"slug":459},"Wisconsin",21,"wisconsin",{"state":461,"count":462,"slug":463},"Utah",20,"utah",{"state":465,"count":466,"slug":467},"Indiana",18,"indiana",{"state":469,"count":470,"slug":471},"Connecticut",17,"connecticut",{"state":473,"count":470,"slug":474},"Washington","washington",{"state":476,"count":477,"slug":478},"Georgia",16,"georgia"]